Post on 07-May-2015
description
MS UpdateMS Update
Gavin GiovannoniGavin GiovannoniBarts and The London School of Medicine and DentistryBarts and The London School of Medicine and Dentistry
CLINICAL SERVICE
Dr Janet Williamson National Director, NHS Improvement
www.ms-res.org
Gastrostomy
Primary Care Referral Diagnosis Minimal impairment
Moderateimpairment
Severeimpairment
End oflife care
Prevention
Cognition
Depression
Fatigue
Bladder
Bowel
Sexual dysfunction Tremor
Pain
Swallowing
Spasticity
Falls
Balance problems
Insomnia
Restless legs
Studying
Employment
RelapsesDMTs
Fertility
Rehab
Suprapubiccatheter
Intrathecal baclofern
Palliative Care
Physiotherapy
Speech therapy
OccupationalTherapy
Nurse specialists Counselling
Neuroradiology
Neurophysiology
Clinical trials
Gait
Neuroimmunology
Pressure sores
Driving
Anxiety
DMTs
Functional neurosurgery
Oscillopsia
Sexual dysfunction
Pseudobulbar affect
Seizures
Advanced directive
Assisted suicide
Colostomy
Tendonotomy
Relationships
Travel vaccination
Socialservices Legal aid
1st line
2nd line
maintenanceescalation
induction
risks
adverse events
monitoring
disease-free
family counselling
vD
A ‘holistic’ approach to MS
Life expectancyLife expectancy
Survival in MSers is shortened by 8 to 12 yearsSurvival in MSers is shortened by 8 to 12 years
Survival Probability of Norwegian Patients with RRMSSurvival Probability of Norwegian Patients with RRMS(Hordaland County, Western Norway, 1953(Hordaland County, Western Norway, 1953––2003)2003)
RRMS=relapsing-remitting MS.Adapted from Torkildsen NG et al. Mult Scler. 2008;14:1191-1198.
500 5 10 15 20 25 30 35 40 450
10
20
30
40
50
60
70
80
90
100
Surv
ival
(%)
Years After Onset
30 35 40 45 50 55 60 65 70 75 80Approximate Patient Age
General PopulationRRMS95% CI
21-year long-term follow-up of IFNb-1b studytime from study randomization to death
Early treatment (3 years) with IFNb-1b was associated with a 47% reduction in the risk of dying over 21 years compared with initial placebo treatment
Source: Poster Goodin et al AAN 2011
At risk:IFNB-1b 250 µgPlacebo
124123
124120
121117
118109
10488
HR=0.532 (95% CI: 0.314–0.902)46.8% reduction in hazard ratio Log rank, P=0.0173
IFNB-1b 250 µg
Placebo
Disease modificationDisease modification
13
The pipelineThe pipeline
Interferons
Phase I
Phase II
Phase III
Marketed
Anti-proliferationagents
Avonex
Atacicept
CampathRituximab
Novantrone
Rebif
Betaferon/ Extavia
Teriflunomide
Tysabri
Zenapax
Pixantrone
Targeted mAbs/Fc-Ab
Cladribine
Fingolimod
Azathioprine
= oral administration= injectable
Riluzole
Symptomatic Tx
Vaccine, tolerisation
Tovaxin
ATL-1102
MM-093BG12
AJM-300
Nerispirdine
Interferon Tau
Interferon omega
Peg IFN (BIIB017)
Fc- IF
ATX-MS-1467
Firategrast
Ofatumumab
Sativex
Lymphocyte trafficking
TBC4746
MLN-0002
Targeted Immune regulation
PI2301
R1295
Copaxone
Laquinimod
Fampridine SR
683699 (T-0047)
OcrelizumabLY-2127399
Disability
Time
6 months 12 months 24 months
Active
Placebo
6 months
Relapsing MS
1. Delay attacks / onset of MS2. Reduce number of attacks3. Reduce severity of attacks4. Reduce disability5. Delay onset of SPMS
Treat early
Treatmentat diagnosis Intervention
at diagnosis
Time
Disease Onset
Disability
Any Negative EDSS=6 SPMS Wheelchair
% R
isk
Rel
ativ
e to
Lo
w E
xpo
sure
Long-term follow-up 16 yearsIFN-beta exposure 80% vs. 20%
Source: Poster Goodin et al AAN 2011
Emerging DMTs
18
Emerging DMTs for relapsing MSphase 3 & 4
Oral1. Fingolimod – 53% reduction in ARR relative to placebo
2. Cladribine – 55% reduction in ARR relative to placebo
3. BG12 – 53% reduction in ARR relative to placebo
4. Teriflunomide – 31% reduction in ARR relative to placebo
5. Laquinimod – 21% reduction in ARR relative to placebo
Parenteral1. Alemtuzumab (anti-CD52) – 55% reduction in ARR relative to IFNβ-1a
2. Ocrelizumab (anti-CD20) – 80% reduction in ARR relative to placebo3. Daclizumab (anti-CD25) – 54% reduction in ARR relative to placebo
?
Recruiting
Oral therapiesOral therapies
BG12
22
Annualized Relapse Rate at 2 Years(Secondary Endpoint)
0
0.1
0.2
0.3
0.4
0.5
0.6
Placebo(n=408)
BG-12 BID(n=410)
BG-12 TID(n=416)
AR
R (
95%
CI)
*
0.364
0.1720.189
53%reduction
vs. placeboP<0.0001
48%reduction
vs. placeboP<0.0001
*ARR calculated with negative binomial regression, adjusted for baseline EDSS score (≤2.0 vs >2.0), baseline age (<40 vs ≥40), region, and number of relapses in the 1 year prior to study entry.
FingolimodFingolimod
24
LAQUINIMOD
0.1
0.2
0.3
0.4
Annu
aliz
ed R
elap
se R
ate*
Placebo Laquinimod 0.6 mg
0.290.37
IM IFN-β-1a 30 mcg(Avonex®)
0.27
21% ReductionP=0.03
*Adjusted for baseline EDSS, number of relapses in 2-year pre-study, country, baseline T2 lesion volume and GdE-T1 status at baseline scan.
0
29% ReductionP=0.002
PRIMARY ENDPOINT: ANNUALIZED RELAPSE RATE*
27
Vollmer T, et al. Presented at: 5th Joint Triennial Congress of the European and Americas Committee for Treatment and Research in Multiple Sclerosis. October 19-22, 2011. Amsterdam, NL. Abstract 148. Multiple Sclerosis. 2011;17:S507.
Teriflunomide
Teriflunomide significantly reduced relapse rate by 31% in both dose groups vs placebo
0.369
0.370
0.539
0 0.1 0.2 0.3 0.4 0.5 0.6
14 mg
7 mg
Placebo
Ter
iflu
no
mid
e
Adjusteda annualised relapse rate
RRR: 31.2% p=0.0002
RRR: 31.5% p=0.0005
aAdjusted for EDSS score strata at baseline and takes duration of treatment into account
ARR, annualised relapse rate; RRR, relative risk reduction;EDSS, Expanded Disability Status Scale
Injection therapiesInjection therapies
Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis
Results of a Phase II, randomised,placebo-controlled, multicentre trial
Ludwig Kappos, University Hospital, Basel, SwitzerlandDavid Li, University of British Columbia, Vancouver, Canada
Peter A Calabresi, Johns Hopkins University, Baltimore, MD, USAPaul O’Connor, University of Toronto, Toronto, ON, Canada
Amit Bar-Or, McGill University, Montreal, CanadaFrederik Barkhof, VU Medical Center, Amsterdam, The Netherlands
Ming Yin, Genentech Inc, South San Francisco, CA, USADavid Leppert, F Hoffmann-La Roche Ltd, Basel, SwitzerlandRobert Glanzman, F Hoffmann-La Roche Ltd, Nutley, NJ, USA
Jeroen Tinbergen, F Hoffmann-La Roche Ltd, Basel, SwitzerlandStephen L Hauser, UCSF, San Francisco, CA, USA
ECTRIMS, 13–16 OCTOBER 2010, GÖTEBURG, SWEDEN
ARR at Week 24
OCR 2000 mg
0-24(n=55)
OCR 600 mg
0-24(n=55)
Placebo
0-24(n=54)
IFN beta-1a
0-24(n=54)
ARR
0.1690.125
0.636
0.364
0.0
0.2
0.4
0.6
0.8
1.0p=0.0014
p=0.0005
0-24 weeks
80%80% 73%73%
A Randomized, Double-Blind, Placebo-controlled
Study to Evaluate the Safety and Efficacy of
Daclizumab HYP Monotherapy in Relapsing Remitting
Multiple Sclerosis: Primary Results of the
SELECT Trial
Gavin Giovannoni1, Ralf Gold,2 Krzysztof Selmaj,3 Eva Havrdova,4 Xavier Montalban,5 Ernst-Wilhelm Radue,6 Dusan Stefoski,7 Randy Robinson,8 Katherine Riester,9 Jacob Elkins,9 Gilmore O’Neill9
1Queen Mary University of London, Barts and The London School of Medicine and Dentistry, UK2St. Josef-Hospital/Ruhr-University Bochum, Bochum, Germany; 3Medical University of Lodz, Lodz, Poland;4Charles University in Prague, Prague, Czech Republic; 5Hospital Vall d'Hebron University, Barcelona, Spain; 6University Hospital Basel, Basel, Switzerland. 7Rush University Medical Center, Chicago, IL. USA; 8Abbott Biotherapeutics, Redwood City, CA, USA; 9Biogen Idec, Cambridge, MA, USA
Confidential
0.46
0.210.23
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
Annualized Relapse Rate
Estimated from a negative binomial regression model adjusted for number of relapses in 1-year period prior to study entry, baseline EDSS (≤2.5 vs. >2.5), and age (≤35 vs. >35)
34
An
nu
aliz
ed r
elap
se r
ate
Placebo (n=196)
DAC HYP150 mg (n=201)
DAC HYP300 mg (n=203)
54% reduction, P<0.0001
50% reduction, P=0.0002
Confidential
35 © Copyright 2011 Biogen Idec & Select - Company Confidential
SafetySafety
NatalizumabNatalizumab
AFFIRM Highly Active* 1 (n= 148 for TYSABRI, 61 for PBO)
81%
64%
reduction in annualised relapse rate vs. placebo over 2 years (p < 0.001)
reduction in the risk of disability progression, sustained for 24 weeks, as assessed over 2 years (p =0.008)
*Patients with ³ 2 relapses and ³ 1 Gd+ lesion in year prior to entry
1. Natalizumab SmPC
Natalizumab
Treatment – disease modifying: NATALIZUMABTreatment – disease modifying: NATALIZUMAB
Immunological VelcroImmunological Velcro
NATALIZUMAB
Progressive multifocal leukoencephalopathy
Kleinschmidt-DeMasters,et al. N Engl J Med. 2005 Jul 28;353(4):369-74.
Natalizumab PML risk stratification tool
Anti-JC virus antibody status
Negative Positive
Prior immunosuppressant use
Natalizumab treatment>2 Years
Natalizumab treatment>2 Years
No Yes
No Yes No Yes
Lowest HighestRelative PML Risk
< 1 in 10,000< 1 in 10,000 1 in 941 in 941 in 2561 in 256 1 in 6681 in 6681 in 18871 in 1887
Mitoxantrone Mitoxantrone AzathioprineAzathioprineMethotrexateMethotrexate
CyclophosphamideCyclophosphamideMycophenolate Mycophenolate
CladribineCladribineRituximabRituximab
Etc.Etc.
Progressive MSProgressive MS
www.ms-res.orgwww.ms-res.org
Disability
Time
12 months 24 months 36 months
Active
PlaceboProgressive MS
1. Reduce rate of disability progression
Disability
Time
6 months 12 months 24 months
Active
Placebo
6 months
Compared to relapsing MS
1. Delay attacks / onset of MS2. Reduce number of attacks3. Reduce severity of attacks4. Reduce disability5. Delay onset of SPMS
Delayed Progression1 Stabilised Progression2
Improved Function3 Recovered Function4
WHAT ARE YOUR EXPECTATIONS OF A THERAPY FOR PROGRESSIVE MS?WHAT ARE YOUR EXPECTATIONS OF A THERAPY FOR PROGRESSIVE MS?
48
1
2
3
www.ms-res.orgwww.ms-res.org
Active tablet
Placebo tablet
Year 1 Year 2 Year 3560 MS’ers
280 MS’ers
280 MS’ers
Disability
Time
Year 1 Year 2 Year 3
Active
Placebo
Disability
Time
Year 1 Year 2 Year 3
ActivePlacebo
Year 3 Year 4 Year 5~600 MS’ers
~300 MS’ers
300 MS’ers
Year 1 Year 2 Year 6 Year 7
Recruitment Trial Data analysis ? Registration
7 years
Petzold et al. J Neurol Neurosurg Psychiatry. 2005 Feb;76(2):206-11.
Spinal fluid neurofilament levels
Spinalfluid
neurofilament levels
Disability (EDSS) and 3 years
Axonal damage in relapsing MS is markedly reduced by natalizumab
Gunnarsson et al. Ann Neurol 2010; Epub.
=
Recruitment Trial Data analysis
6 months
6 months 60 MS’ers
6 months
LP1 LP2 LP3
30 MS’ers active tablet
30 MS’ers placebo tablet
2 years
6 months
600 MS’ers for 7 years 60 MS’ers for 2 years
3 LPs = 10x as many trials in a ⅓ of the time
New paradigm
Can we make LPs safer?
Two types of spinal needle tips: the Quincke and SprotteTwo types of spinal needle tips: the Quincke and Sprotte
Evans R W et al. Neurology 2000;55:909-914
Traumatic
or
cutting needle
Atraumatic
or
non-cutting needle
Ultrasound-guide lumbar puncturesUltrasound-guide lumbar punctures
Brain Brain atrophyatrophy
or or shrinkageshrinkage
Kappos et al. N Engl J Med. 2010 Feb 4;362(5):387-401.
Progressive MSProgressive MS• Two PPMS clinical trialsTwo PPMS clinical trials
• FingolimodFingolimod• OcrelizumabOcrelizumab
• One SPMS clinical trialOne SPMS clinical trial• NatalizumabNatalizumab• ? Oxcarbazepine? Oxcarbazepine
• Symptomatic treatmentsSymptomatic treatments• SativexSativex• Fampridine (Fampyra)Fampridine (Fampyra)
Walking and spasticityWalking and spasticity
Sustained-release oral fampridine in multiple sclerosis:Sustained-release oral fampridine in multiple sclerosis:a randomised, double-blind, controlled triala randomised, double-blind, controlled trial
Goodman et al. Lancet 2009; 373: 732–38.
ConclusionsConclusions• Current first-line therapies are only moderately effectiveCurrent first-line therapies are only moderately effective
• Safe, but are associated with troublesome side effects and poor adherenceSafe, but are associated with troublesome side effects and poor adherence• Escalation therapies (Escalation therapies (NatalizumabNatalizumab))
• More effective but serious adverse effectsMore effective but serious adverse effects• JCV testing optimises risk:benefitJCV testing optimises risk:benefit
• A healthy drug pipeline A healthy drug pipeline • 3 oral agents look to emerge from the pipeline3 oral agents look to emerge from the pipeline• AlemtuzumabAlemtuzumab, , daclizumabdaclizumab and and anti-CD20anti-CD20 most exciting of the parenteral most exciting of the parenteral
therapies in phase 2/3therapies in phase 2/3• Symptomatic treatmentsSymptomatic treatments
• SativexSativex• FampridineFampridine
• Patient factors – risk assessment tools, education and a focus on wellnessPatient factors – risk assessment tools, education and a focus on wellness• Neuroprotection – several phase 2 trials currently been undertaken with oral Neuroprotection – several phase 2 trials currently been undertaken with oral
agentsagents
Questions?Questions?
www.ms-res.orgwww.ms-res.org
g.giovannoni@qmul.ac.ukg.giovannoni@qmul.ac.uk
Prof. Gavin GiovannoniProf. Gavin GiovannoniDepartment of NeurologyDepartment of NeurologyRoyal London HospitalRoyal London HospitalWhitechapel, London E1 1BBWhitechapel, London E1 1BB